Premium
Human Cardiac Organoids for Disease Modeling
Author(s) -
Nugraha Bramasta,
Buono Michele F.,
Boehmer Lisa,
Hoerstrup Simon P.,
Emmert Maximilian Y.
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1286
Subject(s) - organoid , induced pluripotent stem cell , drug discovery , computational biology , personalized medicine , disease , human disease , biology , neuroscience , bioinformatics , computer science , medicine , pathology , embryonic stem cell , gene , genetics
Human cardiac drug discovery and disease modeling face challenges in recapitulating cellular complexity and animal‐to‐human translation due to the limitations of conventional 2D cell culture and animal models. The development of human cardiac organoid technologies could help in stimulating and maintaining differentiated cell functions for extended periods of time. By closely mimicking in vivo organ functions in vitro they could thereby help in overcoming the obstacles mentioned above. Through the construction of human cardiac organoids from pluripotent stem cell–derived cells, derived from patients with specific known genotypes and phenotypes, more complex and robust in vitro tools have recently become available for disease modeling. In this review, we will describe the relevance and importance of evolving organoid platforms in disease biology. We further provide examples of cardiac organoid platforms, which may lead the way toward future personalized medicine and drug discovery.